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Abstract
Background: Tumor-infiltrating T cells are associated with survival in epithelial ovarian cancer (EOC), but their functional
status is poorly understood, especially relative to the different risk categories and histological subtypes of EOC.
Methodology/Principal Findings: Tissue microarrays containing high-grade serous, endometrioid, mucinous and clear cell
tumors were analyzed immunohistochemically for the presence of lymphocytes, dendritic cells, neutrophils, macrophages,
MHC class I and II, and various markers of activation and inflammation. In high-grade serous tumors from optimally
debulked patients, positive associations were seen between intraepithelial cells expressing CD3, CD4, CD8, CD45RO, CD25,
TIA-1, Granzyme B, FoxP3, CD20, and CD68, as well as expression of MHC class I and II by tumor cells. Disease-specific
survival was positively associated with the markers CD8, CD3, FoxP3, TIA-1, CD20, MHC class I and class II. In other
histological subtypes, immune infiltrates were less prevalent, and the only markers associated with survival were MHC class
II (positive association in endometrioid cases) and myeloperoxidase (negative association in clear cell cases).
Conclusions/Significance: Host immune responses to EOC vary widely according to histological subtype and the extent of
residual disease. TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally
debulked patients.
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Introduction
Ovarian cancer is the most deadly gynecologic cancer, affecting
more than 190,000 women worldwide each year (International
Agency for Research on Cancer). Delayed diagnosis and the
presence of widely disseminated disease account for the high
mortality associated with the disease. Additionally, while a large
percentage of patients initially respond well to cytoreductive
surgery and standard chemotherapy, the disease usually recurs
within 2-5 years as residual tumor cells develop resistance to
chemotherapy [1,2]. Although prognosis is often poor, numerous
favorable prognostic indicators have been described, including
early stage, low grade and optimal surgical debulking [3,4].
Several recent studies have analyzed the influence of host
immunity on disease prognosis. Tumor-infiltrating CD3+ T cells
are strongly associated with favorable prognosis, specifically when
CD3+ cells are localized within tumor epithelium [5-9]. These
findings have been extended to the CD8+ T cell subset in
particular [10-17], suggesting that cytotoxic T lymphocytes (CTLs)
play an important role in the antitumor immune response.
Accordingly, other factors associated with CTL responses are also
positively associated with survival, including interferon-c (IFN- c)
[18,19], the IFN- c receptor [20], interferon regulatory factor
(IRF)-1 [21], IL-18 [22], TNF-a [23], MHC class I [24-26], and
MHC class I antigen processing machinery [17].
In contrast to CD8+ T cells, several studies have indicated that
tumor-infiltrating CD25+FoxP3+ T cells (referred to as regulatory
T cells or Tregs) are associated with decreased survival [10,27-29].
Tregs have the ability to suppress proliferation, cytokine
production, and cytolytic activity of CD4+ and CD8+ T cells by
mechanisms involving cell-to-cell contact and the release of
cytokines such as TGF-b [30,31]. Tregs can also induce an
immunosuppressive phenotype in other cell types such as
macrophages [32]. Although Tregs have been associated with
poor prognosis in many cancers, several exceptions have recently
been reported. Leffers et. al. found that FoxP3+ infiltrates in
advanced stage EOC were associated with increased survival [14].
Similar findings have been reported in colorectal cancer [33] and
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can play a positive role in anti-tumor and anti-viral immunity
[37,38]. The precise role of regulatory T cells in cancer outcomes
warrants further consideration given that several groups are
attempting to enhance tumor immunity by depleting FoxP3+
Tregs from cancer patients [39-44], including EOC patients [45].
In addition to Tregs, other cell types reportedly play an
immunosuppressive role in EOC. For example, plasmacytoid dendritic
cells contribute to immunosuppression by promoting the development
or recruitment of interleukin-10-producing CD4+ and CD8+
regulatory T cells [46,47]. Myeloid dendritic cells (MDCs) impair T
cell immunity by expressing B7-H1, a ligand for the inhibitory receptor
PD-1 found on T cells [48]. Monocytes and macrophages in the EOC
microenvironment can be polarized toward a so-called M2 phenotype,
which is typified by the expression of IL-10, TGF-b and scavenger
receptors and is thought to promote tumor progression [49,50,51].
Under the influence of IL-6 and IL-10, macrophages in EOC can also
express B7-H4, which inhibits T cell proliferation [52]. Macrophages
also produce CCL22, which promotes Treg recruitment to the tumor
environment [32]. Finally, expression of the inflammatory mediator
COX-2 in tumor epithelium has been associated with reduced
lymphocyte infiltration and poor prognosis in EOC [13,53].
With the advent of tumor tissue microarray (TMA) technology,
a large number of retrospective studies have investigated the
relationship between tumor-infiltrating immune cells and progno-
sis in EOC and other cancers. However, most studies focus on one
or a few markers, such that associations between different
immunological factors may be missed. Additionally most studies
fail to address the different histological subtypes of EOC, which
are now recognized to behave as distinct diseases [54]. As a result,
there are inconsistencies and unresolved issues in the literature
concerning the prognostic significance of different immune cell
infiltrates. To address this, we analyzed several large series of EOC
tumors, including high-grade serous, endometrioid, clear cell and
mucinous subtypes, for the presence of various immune cell
infiltrates and inflammatory markers. Our results reveal that high-
grade serous tumors have a distinct immunological profile that is
strongly associated with patient survival.
Results
Intraepithelial T cells and associated functional markers
in high-grade serous EOC
We initially investigated the relationship between immune
infiltrates and survival in a cohort of 199 high-grade serous EOC
patients. We chose to first focus on high-grade serous cases, as the
other histological subtypes exhibit distinct biological and clinical
properties that are potentially confounding [54,55]. This initial
cohort was restricted to patients who had undergone optimal
cytoreduction (i.e., without evidence of macroscopic residual
disease). Patient characteristics are shown in Table 1.
The tumors in this initial cohort had been previously assessed by
immunohistochemistry (IHC) for a variety of lymphocyte markers,
including CD3, CD4, CD8, CD20 and Granzyme B [12].
Intraepithelial lymphocytes (i.e., lymphocytes within the epithelial
component of the tumor) were scored as either present (i.e. one or
more intraepithelial lymphocytes present in at least one of two 0.6
mm cores) or absent. We re-analyzed this data focusing exclusively
on high-grade serous cases. We found that 83.2% (163/196) of
evaluable high-grade serous tumors were positive for intraepithe-
lial CD3+ T cells, whereas CD4+ and CD8+ intraepithelial cells
were found in 53.4% (103/193) and 84.0% (163/194) of evaluable
tumors, respectively (Fig. 1A&B and data not shown). CD4+ and
CD8+ cellular infiltrates showed a strong positive association
(p,0.0001). Table 2 shows statistical associations for these and all
other markers studied in this initial cohort.
While the above markers indicate which lymphocyte subsets are
present in tumors, they do not reveal their activation state. To
address this issue, we analyzed tumors for expression of CD45RO,
OX40 and CD25, which are expressed by activated T cells
[56,57]. Using the same scoring criteria as above, 70.6% (132/
187) of tumors were positive for intraepithelial CD45RO+ cells,
and 49.7% (96/193) were positive for intraepithelial CD25+ cells
(Fig. 1C&E). By contrast, only 7.0% (11/158) of tumors were
positive for intraepithelial OX40+ cells (Fig. 1D). In pair-wise
comparisons, CD45RO, CD25 and OX40 were all positively
associated (Table 2). Moreover, CD45RO and CD25 were both
associated with the presence of CD3+, CD4+ and CD8+ cells.
OX40 showed a similar trend, but this did not reach statistical
significance, likely due to the low number of positive cases.
To investigate the differentiation state of tumor-infiltrating T
cells, tissues were analyzed for intraepithelial cells expressing TIA-
1 and Granzyme B, which are markers of CD8+ cytotoxic T cells
and NK cells [58-60]. A majority of tumors (66.5%, 127/191)
were positive for intraepithelial TIA-1+ cells (Fig. 1F), and about
half of tumors (45.6%, 88/193) were positive for intraepithelial
Granzyme B+ cells (Fig. 1G). There was a highly significant
association between TIA-1+ and Granzyme B+ cells (p,0.0001).
Moreover, in pair-wise comparisons, TIA-1+ and Granzyme B+
cells were each associated with the activation markers CD45RO,
CD25 and OX40. Finally, TIA-1+ and Granzyme B+ cells were
each associated with the presence of CD3+, CD4+ and CD8+ cells
(Table 2). To examine whether TIA-1 and Granzyme B
Table 1. Clinical characteristics of the optimally debulked
high-grade serous EOC patient cohort.
Age at surgery (years)
Mean 61.00
Std dev 11.48
Range 37.59-85.96
Median 60.08
* Overall Survival (years)
Mean 5.59
Std dev 3.47
Range 0.4-17.4
Median 4.91
Silverberg Grade
10
25 6
31 4 3
Unknown 0
Stage
I4 9
II 85
III 65
IV 0
Unknown 0
Total number of evaluable patients 199
*There were no deaths due to causes other than ovarian cancer, therefore
disease-specific and overall survival were equivalent.
doi:10.1371/journal.pone.0006412.t001
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PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6412Figure 1. Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing markers of T cell
differentiation and activation. (A) CD4, (B) CD8, (C) CD45RO, (D) OX40, (E) CD25, (F) TIA-1, (G) Granzyme B, and (H) FoxP3. 40X objective.
doi:10.1371/journal.pone.0006412.g001
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examined tumors for the NK cell markers CD56 and CD57. For
both markers, there were either few or no infiltrates at all within
the tumor epithelium (data not shown), indicating that the TIA-1+
and Granzyme B+ infiltrates were most likely T cells.
Finally, tumors were analyzed for the presence of intraepithelial
cells expressing FoxP3, which in humans is a marker of regulatory
T cells and activated T cells [61,62]. About half of tumors (52.9%,
100/189) were positive for intraepithelial FoxP3+ cells (Fig. 1H).
There was a strong association between FoxP3+ and CD25+ cells
(p,0.0001), and FoxP3+ and CD25+ cells were each strongly
associated with CD4+ cells (p,0.0001 for both markers). Thus,
consistent with previous reports [10,14,27,28], a significant
proportion of tumors contained intraepithelial infiltrates with
markers characteristic of Tregs (CD4+,CD25+, and FoxP3+).
MHC class I and II in high-grade serous EOC
We analyzed tumor cells for expression of MHC class I and II
using a four-point scale (negative, focal [,10%], patchy [10-50%]
or diffuse [.50%]). All evaluable tumors (185/185) expressed
MHC class I to some degree (i.e., focal, patchy or diffuse), indicating
they could theoretically present antigen to CD8+ T cells. For
Table 2. p-values for Chi-square tests of associations between immunohistochemical markers in the optimally debulked high-
grade serous EOC cohort.
CD3 CD8 CD4 CD45R0 CD25 OX40 TIA-1 GrB
1
CD3 ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.16 ,0.0001 ,0.0001
CD8 ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.15 ,0.0001 ,0.0001
CD4 ,0.0001 ,0.0001 0.0021 ,0.0001 0.049 0.0013 0.0001
CD45RO ,0.0001 ,0.0001 0.0021 ,0.0001 0.031 ,0.0001 ,0.0001
CD25 ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.0040 ,0.0001 ,0.0001
OX40 0.16 0.15 0.049 0.031 0.0040 0.012 0.044
TIA-1 ,0.0001 ,0.0001 0.0013 ,0.0001 ,0.0001 0.012 ,0.0001
GrB
1 ,0.0001 ,0.0001 0.0001 ,0.0001 ,0.0001 0.044 ,0.0001
FoxP3 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.47 ,0.0001 ,0.0001
MHC I
2 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.18 ,0.0001 0.0001
MHC II
3 0.0078 0.0009 0.013 0.0004 0.0001 0.38 0.0006 0.016
CD20 ,0.0001 ,0.0001 0.0006 0.0036 0.0006 0.13 ,0.0001 ,0.0001
CD1a 0.11 0.096 0.046 0.21 0.27 0.030 0.31 0.48
CD68 ,0.0001 0.0001 0.0028 0.0019 0.0006 0.23 0.0005 0.0007
MPO
4 0.89 0.53 0.034 0.90 0.78 0.33 0.67 0.49
COX-2
5 0.75 0.64 0.55 0.64 0.74 0.76 0.42 0.70
FoxP3 MHC I
2 MHC II
3 CD20 CD1a CD68 MPO
4 COX2
5
CD3 ,0.0001 ,0.0001 0.0078 ,0.0001 0.11 ,0.0001 0.89 0.75
CD8 ,0.0001 ,0.0001 0.0009 ,0.0001 0.096 0.0001 0.53 0.64
CD4 ,0.0001 ,0.0001 0.013 0.0006 0.046 0.0028 0.034 0.55
CD45RO ,0.0001 ,0.0001 0.0004 0.0036 0.21 0.0019 0.90 0.64
CD25 ,0.0001 ,0.0001 0.0001 0.0006 0.27 0.0006 0.78 0.74
OX40 0.47 0.18 0.38 0.13 0.030 0.23 0.33 0.76
TIA-1 ,0.0001 ,0.0001 0.0006 ,0.0001 0.31 0.0005 0.67 0.42
GrB
1 ,0.0001 0.0001 0.016 ,0.0001 0.48 0.0007 0.49 0.70
FoxP3 ,0.0001 ,0.0001 0.0009 0.35 0.0001 0.42 0.82
MHC I
2 ,0.0001 ,0.0001 0.0015 0.13 0.035 0.61 0.17
MHC II
3 ,0.0001 ,0.0001 0.023 0.11 0.22 0.39 0.30
CD20 0.0009 0.0015 0.023 0.87 0.029 0.60 0.13
CD1a 0.35 0.13 0.11 0.87 0.52 0.046 0.84
CD68 0.0001 0.035 0.22 0.029 0.52 0.43 0.30
MPO
4 0.42 0.61 0.39 0.60 0.046 0.43 0.51
COX-2
5 0.82 0.17 0.30 0.13 0.84 0.30 0.51
1GrB = Granzyme B.
2MHC I = MHC class I.
3MHC II = MHC class II.
4MPO = myeloperoxidase.
5COX-2 = Cyclooxygenase-2.
doi:10.1371/journal.pone.0006412.t002
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considered positive (Fig. 2A&B). Using this threshold, 85.4% (158/
185) of tumors were positive for MHC class I. MHC class I was
positively associated with all three T cell subsets (CD3, CD4, and
CD8), the activation markers CD45RO and CD25, and the
differentiation markers TIA-1, Granzyme B and FoxP3 (Table 2).
A large majority of tumors (86.5%, 166/192) expressed MHC
class II to some degree (i.e., focal, patchy or diffuse), indicating they
could theoretically present antigen to CD4+ Tc e l l s .A sw i t hM H C
class I, only the highest category (diffuse, .50%) was considered
positive for statistical analyses (Fig. 2 C&D). Using this threshold,
41.1% (79/192) of tumors were positive for MHC class II. MHC
class II was strongly associated with MHC class I (p,0.0001).
Accordingly, MHC class II was positively associated with all three T
cellsubsets(CD3, CD4,andCD8), the activation markers CD45RO
and CD25, and the differentiation markers TIA-1, Granzyme B and
FoxP3 (Table 2). Similar to the results for MHC class I, the
expression of MHC class II in tumor epithelium was positively
associated with various T cell markers, including CD3, CD4, CD8,
CD45RO, TIA-1, Granzyme B, CD25 and FoxP3 (Table 2).
Intraepithelial B cells in high-grade serous EOC
Tissues were stained with an antibody to CD20, which is
expressed by B cells from the naı ¨ve to memory stages of
differentiation [63]. Intraepithelial CD20+ cells were found in
41.9% (83/198) of evaluable tumors (Fig. 3A). CD20+ infiltrates
were strongly associated with all three T cell subsets (CD3, CD4,
and CD8); the activation markers CD45RO and CD25; the
differentiation markers TIA-1, Granzyme B and FoxP3; and both
MHC class I and II (Table 2).
Figure 2. Immunohistochemical analysis of high-grade serous EOC tumors showing (A,B) high and low expression of MHC class I,
(C,D) high and low expression of MHC class II, and (E,F) high and low expression of COX-2. 40X objective.
doi:10.1371/journal.pone.0006412.g002
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macrophages in high-grade serous EOC
Tumors were analyzed for the presence of immature and
mature dendritic cells by staining for CD1a and CD208,
respectively. A minority of tumors (13.4%, 23/172) contained
intraepithelial CD1a+ cells (Fig. 3B). No significant association
with any of the intraepithelial lymphocyte markers (CD3, CD8 or
CD20), activation markers (CD45RO or CD25), differentiation
markers (TIA-1, Granzyme B or FoxP3) or MHC class I or II
(Table 2) was seen, potentially due to the low number of CD1a+
cells. In contrast to CD1a, none of the tumors scored positive for
intraepithelial CD208+ cells. Parallel analysis of tonsil tissue
revealed the presence of many CD208+ cells, thereby validating
the IHC procedure.
About half of tumors (54.7%, 87/159) contained intraepithelial
cells expressing the macrophage marker CD68 (Fig. 3D). CD68
was positively associated with several lymphocyte markers (CD3,
CD8 and CD20), activation markers (CD45RO and CD25),
differentiation markers (TIA-1, Granzyme B and FoxP3) and
MHC class I (Table 2). To assess the presence of granulocytes, the
TMA was stained for myeloperoxidase. Twenty four percent (37/
154) of tumors contained myeloperoxidase-expressing cells
(Fig. 3C), however these showed no significant associations with
other markers, with the exception of CD4 (p=0.034).
The COX-2 enzyme has been associated with inferior survival
in EOC when expressed in the epithelial component of the tumor
[53]. Therefore, tumors were scored for expression of COX-2 in
the epithelial component using a four-point scale (negative,
equivocal [0-1%], patchy [1-50%] or diffuse [.50%])
(Fig. 2E&F). Two-thirds of tumors (66.5%, 111/167) were positive
for COX-2 (i.e., patchy or diffuse staining). In contrast to reports
in ovarian, cervical, and other cancers, [13,64,65], the expression
of COX-2 was not significantly associated with any of the immune
infiltrates studied (Table 2).
Associations between immune infiltrates and patient
survival in high-grade serous EOC
Kaplan-Meier analysis was performed to assess the association
between various immune infiltrates and disease-specific survival
(DSS). Consistent with prior reports [5-7,10-17], intraepithelial
CD3+ and CD8+ cells were associated with increased DSS
(p=0.0009 and 0.0008 respectively) (Fig. 4A&B). Intraepithelial
CD4+ cells showed a trend towards increased DSS, but this was
not statistically significant (Fig. 4C). The NK cell markers CD56
and CD57 showed no association with DSS (data not shown).
Intriguingly, intraepithelial CD20+ cells were associated with
increased DSS (p=0.0033) (Fig. 4E). Furthermore, the combina-
tion of CD8+ and CD20+ infiltrates was associated with
significantly increased DSS over tumors that contained CD8+
infiltrates but not CD20+ infiltrates (median 4432 days vs. 2279
days, p=0.0115) (data not shown).
In contrast to lymphocyte markers, the dendritic cell marker
CD1a showed no association with DSS, possibly due to the low
number of tumors containing CD1a+ cells. Likewise, the markers
CD68, COX-2 and myeloperoxidase showed no association with
DSS (Fig. 4F and data not shown).
Given the association between CD8+ T cells and DSS, we
evaluated other canonical features of active CTL responses. DSS
was positively associated with intraepithelial TIA-1+ cells
(p=0.0003), as well as expression of MHC class I and II by
Figure 3. Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing (A) CD20 (B cells), (B)
CD1a (immature DCs), (C) Myeloperoxidase (granulocytes), and (D) CD68 (macrophages). 40X objective.
doi:10.1371/journal.pone.0006412.g003
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PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6412Figure 4. Immune infiltrates and survival in ovarian cancer. Kaplan-Meier curves showing disease-specific survival for patients scored as
positive or negative for (A) CD3, (B) CD8, (C) CD4, (D) FoxP3, (E) CD20, (F) CD68, (G) TIA-1, (H) Granzyme B, (I) MHC Class I and (J) MHC Class II. Data
were derived from optimally debulked patients with high-grade serous EOC.
doi:10.1371/journal.pone.0006412.g004
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Tumors that contained both CD8+ and TIA-1+ infiltrates were
associated with increased DSS compared to CD8+ TIA-1-negative
tumors (p=0.0025). Several other T cell markers, including
Granzyme B, CD45RO and CD25, showed trends toward
increased DSS but did not reach statistical significance (Fig. 4H
and data not shown). OX-40 showed no apparent trend or
association with DSS, possibly due to low numbers of positive
cases (data not shown).
In apparent contrast to reports that regulatory T cells are
associated with poor prognosis, the presence of intraepithelial
FoxP3+ cells was associated with increased DSS (p=0.010)
(Fig. 4D). Moreover, tumors that were triply positive for
intraepithelial CD4+, FoxP3+ and CD25+ cells showed a trend
towards increased survival, although this fell short of statistical
significance (p=0.059). Likewise, tumors positive for both
intraepithelial CD8+ and FoxP3+ cells showed a trend toward
increased DSS compared to tumors that were positive for CD8+
cells but negative for FoxP3+ cells; however, this trend did not
reach statistical significance (p=0.052). Thus, by multiple
analyses, tumor-infiltrating FoxP3+ cells showed a trend or
statistically significant association with increased DSS.
The association between immune infiltrates and survival
is dependent on the extent of residual disease
T cell infiltrates are reportedly more prevalent in patients with
optimal versus suboptimal cytoreduction [5,66]. To investigate
whether this was true for other lymphocyte markers, we analyzed
an additional cohort of 220 high-grade serous cases from patients
known to have macroscopic residual disease following primary
cytoreductive surgery. We focused on CD8+ infiltrates, as well as the
three novel prognostic markers from the preceding analysis (i.e.,
FoxP3, TIA-1 and CD20). Compared to the optimally debulked
patient cohort, patients with macroscopic residual disease had a
significantly lower prevalence of CD8+ (58.5%), FoxP3+ (20.2%),
TIA-1+ (39.5%) and CD20+ (16.3%) infiltrates (p,0.0001 for all
markers).InKaplan-Meieranalysisofthesefourmarkers,onlyCD8+
infiltrates had a significant association with survival (p=0.0044) in
patients with macroscopic residual disease (data not shown).
The association between immune infiltrates and survival
is dependent on histological subtype
The preceding results were based exclusively on high-grade
serous EOC cases. To assess the association between immune
infiltrates and DSS in other histological subtypes of EOC, we
performed the same analyses using an additional 288 EOC tumors
of the following histological subtypes: mucinous (n=31), endome-
trioid (n=125) and clear cell (n=132). These additional tumor
specimens were from a previously described cohort of optimally
debulked patients [12].
In general, immune infiltrates were less prevalent in the other
histological subtypes compared to the high-grade serous cases
discussed previously. This was true for all lymphocyte markers
studied (i.e., CD3, CD8, CD4, CD45RO, CD25, FoxP3, TIA-1,
Granzyme B, and CD20) (Fig. 5). The difference was most striking
for the markers FoxP3, CD25 and CD20. After the high-grade
serous cases, the next highest frequency of immune infiltrates was
seen in the endometrioid subtype (Fig. 5).
We examined the association between immune infiltrates and
DSS in the endometrioid and clear cell subtypes; the number of
mucinous cases was too small to perform robust statistical analysis.
For endometrioid cases, the only significant association found was
between MHC class II expression and increased DSS (p=0.039)
(data not shown). For clear cell cases, the only significant
association found was between the presence of myeloperoxidase-
positive infiltrates and decreased DSS (p=0.040, data not shown).
Thus, the relationship between immune infiltrates and survival
differs greatly between histological subtypes of EOC.
Figure 5. Prevalence of immune infiltrates and other markers across different histologic subtypes of EOC. Bars indicate the percentage
of tumors scoring positive for intrapithelial cells expressing CD3, CD8, CD4, CD45RO, CD25, FoxP3, TIA-1, Granzyme B, CD20 and CD68. Expression of
MHC class I and II by tumor epithelium is also shown. Data were derived from optimally debulked patients.
doi:10.1371/journal.pone.0006412.g005
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We systematically examined the relationship between immune
infiltrates and patient survival in three large EOC series. In accord
with Clarke et al. [12], we found that high-grade serous tumors
have a distinct immunological profile compared to the endome-
trioid, clear cell and mucinous subtypes. Furthermore, we found
that immune infiltrates were generally more prevalent in tumors
from patients with optimal cytoreduction. FoxP3, TIA-1 and
CD20 emerged as novel immunological markers associated with
increased patient survival. Our results highlight the importance of
histological subtype in the immunobiology of EOC, which may
have important implications for the immunotherapy of this family
of diseases.
Intraepithelial lymphocytes (i.e., cells expressing CD3, CD4,
CD8, FoxP3 or CD20) were more prevalent in high-grade serous
cases, followed by endometrioid cases. Moreover, intraepithelial
lymphocytes were more prevalent in tumors from optimally
debulked patients compared to patients with macroscopic residual
disease. A number of biological features of tumors appear to
influence the density of lymphocytic infiltrates. (a) T cell infiltrates
are positively associated with expression of MHC class I and II by
tumor cells (Table 2), as well as MHC class I antigen processing
machinery [15-17,67], suggesting that antigen presentation may
be an important determinant of T cell infiltration. (b) In accord
with this notion, tumors with loss or mutation of the BRCA1 or
p53 genes have an increased density of tumor-infiltrating T cells
[12,66]. This suggests that defective DNA repair and the ensuing
genomic instability in tumors may lead to the generation of neo-
antigens that trigger host T cell responses. (c) Signaling molecules
also play a role, as the density of tumor-infiltrating T cells is
negatively associated with expression of VEGF, B7-H1/PD-L1
and endothelin B receptor by tumors [5,11,68] and positively
associated with expression of the chemokines CXCL9, CCL21,
CCL22, CCL2 and CCL5 [5,28,69]. (d) Finally, two groups have
reported gene expression profiles that correlate with the presence
of tumor-infiltrating T cells in EOC [12,70]. These latter studies
confirm some of the above associations (e.g., MHC class I and II,
beta 2 microglobulin, TAP1 and 2) and identify new factors
associated with T cell infiltrates (e.g., IL-15, IL-32 and numerous
interferon-induced genes). Presumably one or more of the above
factors accounts for the observed enrichment of tumor-infiltrating
lymphocytes in high-grade serous and optimally cytoreduced
cases.
Although the association between intraepithelial CD8+ T cells
and increased survival in EOC is a highly reproducible finding
[10-17], relatively little is known about the functional phenotype of
these CD8+ T cells. Several lines of evidence suggest a classic
cytolytic response underlies favorable outcomes. For example,
others have reported positive associations between survival and
intratumoral expression of IFN- c [18,19], the IFN- c receptor
[20], as well as numerous interferon-responsive genes such as
MHC class I [24-26], MHC class I antigen processing machinery
[17], MHC class II [15,16], and IRF-1 [21]. IL-18 [22] and TNF-
a [23] also appear to be important components of the T cell
response, as both cytokines are positively associated with survival.
We examined two components of cytolytic granules, Granzyme B
and TIA-1, both of which showed an association with CD8+ T cell
infiltrates. Of these two markers, only TIA-1 showed a statistically
significant association with survival in high-grade serous cases
(Fig. 4). TIA-1+ cells have also been described in medullary breast
cancer [71,72] and melanoma [73], where they are associated with
favorable prognostic features. By contrast, tumor-infiltrating TIA-
1+ cells are associated with decreased survival in lymphoma [74-
78]. Interestingly, TIA-1 is not simply a marker of cytolytic
granules; it is an RNA binding protein involved in post-
transcriptional mRNA regulation [79]. It remains to be deter-
mined whether the association between intraepithelial TIA-1+
cells and survival in EOC is due to the role of this protein in
cytolytic granule function or mRNA regulation.
Treg infiltrates have previously been associated with decreased
survival in ovarian EOC [10,27,28]. However, in the present study
and one other recent report [14], FoxP3+ infiltrates were
associated with increased survival. These seemingly contradictory
findings may be attributable to several factors. First, not all studies
take into consideration the histological subtypes of EOC, or the
extent of residual disease; in the present study, FoxP3+ cells were
only associated with survival in high-grade serous tumors from
optimally debulked patients. Second, a variety of antibodies have
been used to detect FoxP3, which can lead to discordant results
[80]. Third, different scoring criteria may be used. For example,
the precise intratumoral location of Tregs is an important
determinant of prognosis in gastric cancer [81]. Fourth, the
molecular markers used to define Tregs differ between studies.
Although FoxP3 is still regarded as the most reliable marker of
Tregs in human cancer [82,83], it can also be expressed by
epithelial tumor cells [84-86] and in vitro activated CD4+ and
CD8+ T cells [87-95]. For these reasons, some studies include
CD25 as a second marker of Tregs [10,28]. However, like FoxP3,
CD25 is potentially expressed by effector T cells, so it is not clear
that dual staining for FoxP3 and CD25 more accurately identifies
Tregs [89,96]. Other characteristics of Tregs include high
expression of GITR and CTLA-4 and low expression of CD127
and CD49d and [97,98], however these markers are technically
difficult to assess on paraffin-embedded TMAs.
These technical considerations notwithstanding, there is mount-
ing evidence that tumor-infiltrating FoxP3+ cells are associated
with a favorable prognosis in EOC, colorectal cancer, head and
neck cancer, and lymphoma [14,33,-36,99-102]. How might
FoxP3+ T cells promote favorable outcomes? In the present study,
FoxP3+ cells were strongly associated with other effector T cells,
and similar results have been reported in melanoma [103]. Thus,
FoxP3+ cells may simply be an indicator of a strong CD8+ T cell
response, which might outweigh any immunosuppressive effects of
FoxP3+ cells. Alternatively, subsets of human FoxP3+ T cells have
recently been shown to have a pro-inflammatory, IL-17-producing
phenotype [104-106]. Indeed, CD4+ T cells can be skewed toward
this so-called Th17 phenotype by exposure to TGF-b in
combination with IL-6, IL-1 or IL-23 [107-109]. These factors
are present in the EOC tumor environment [8], and accordingly,
Th17 cells have been reported in EOC [110-112]. Thus, the
association between FoxP3+ cells and increased survival could
potentially reflect an underlying Th17-like anti-tumor response.
Clearly, more work is required to determine the extent to which
FoxP3+ T cells in EOC represent Tregs versus Th17 or other
effector T cells.
The observation that intraepithelial CD20+ infiltrates are
associated with increased DSS is a novel finding in EOC. Dong
et. al. reported that B cells in ascites were associated with shorter
survival in EOC [113], however their study focused on B cells in
peritoneal and pleural effusions collected after chemotherapy,
which by definition constitutes a poor outcome cohort. Indeed, in
the present study, intraepithelial CD20+ B cells showed no
association with survival in patients with high-risk, suboptimally
debulked disease. Tumor-infiltrating CD20+ B cells are a hallmark
of medullary breast cancer and have been proposed to mediate a
favorable prognosis [114,115]. Moreover, the presence of a B cell
transcriptional signature in node-negative breast cancer is
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cancer represent clonally expanded populations, express somati-
cally hypermutated IgG molecules, and recognize target antigens
such as ganglioside D3 and surface-translocated actin
[114,115,117-120]. It is unclear how tumor-infiltrating B cells
promote favorable outcomes in cancer. In theory, their actions
could be mediated by secreted antibodies, which can promote the
opsonization of tumor antigens, complement-mediated destruction
of tumor cells, or antibody-dependent cellular cytotoxicity. Apart
from producing antibodies, B cells can also present antigen to both
CD4+ and CD8+ T cells [121-131]. In this regard, it is noteworthy
that ovarian tumors show low numbers of CD1a+ dendritic cells;
perhaps CD20+ B cells serve as alternative antigen presenting cells
in the tumor environment. This latter idea fits well with the
observed co-localization of tumor-infiltrating B cells and CD8+ T
cells in EOC, as well as in medullary breast cancer, non-small cell
lung cancer and cervical cancer [72,132-134].
The presence of macrophages has been associated with poor
prognosis in various human cancers [135,136]. However, in
accord with a prior report by Shah et. al. [66], we found no
association between CD68+ infiltrates and survival in EOC.
Importantly, however, CD68 is not a perfect marker of
macrophages, as it is also expressed by dendritic cells and some
non-myeloid cells [137]. Furthermore, CD68 does not distinguish
between macrophages polarized towards the pro-inflammatory
(M1) or tumor-promoting (M2) phenotypes. M1 macrophages
have the capacity to kill tumor cells, whereas M2 macrophages
promote tissue repair and angiogenesis [136]. Similarly, an
immunosuppressive subpopulation of macrophages has been
described in EOC based on expression of the signaling molecule
B7-H4 [52]. Thus, additional functional markers may be required
to fully define the role of macrophages in the immunobiology of
EOC.
While this study focused on the relationship between immune
infiltrates and prognosis after standard treatments, the results may
also inform the design of immunotherapies for EOC. First, our
findings suggest that high-grade serous tumors may be especially
sensitive to T cell responses. Second, our data indicates that, in
patients with residual disease, the influence of T cells may be
overwhelmed by other factors. Third, the positive association
between intraepithelial FoxP3+ cells and survival reported here
and previously [14] prompts a reconsideration of strategies to
deplete regulatory T cells from EOC patients. And fourth, the
association between intraepithelial CD20+ cells and survival
suggests the humoral immune response may play an important
role in anti-tumor immunity that could be exploited therapeuti-
cally in parallel with CD8+ T cell responses.
Materials and Methods
Study subjects
All specimens and clinical data were obtained with informed
written consent under protocols approved by the Research Ethics
Board of the BC Cancer Agency and the University of British
Columbia. The main cohort used for this study consisted of 199
women with high-grade serous ovarian cancer seen at the BC
Cancer Agency from 1984 to 2000 (OvCaRe Ovarian Tumour
Bank, Vancouver, BC, Canada). Tumor tissue was obtained at the
time of primary surgery prior to any other treatment. Patients had
no macroscopic residual disease following surgical debulking. All
patients underwent standard treatment consisting of surgery
followed by standard platinum-based chemotherapy. Table 1
shows the general clinical characteristics of the 199-case cohort.
We also analyzed a second cohort of mucinous (n=31),
endometrioid (n=125) and clear cell (n=132) EOC cases.
Patients in this cohort were also diagnosed from 1984 to 2000,
were optimally cytoreduced, and received platinum-based chemo-
therapy. Finally, we analyzed a third cohort of 220 high-grade
serous EOC patients categorized as extreme risk due to the
presence of residual macroscopic disease. Patients in this cohort
were treated from 1996 to 2000 and received platinum-based
chemotherapy.
Tumor specimens
Tumor tissue was obtained during primary cytoreductive
surgery, fixed in 10% neutral buffered formalin, processed using
standard procedures and embedded in paraffin. A tissue micro-
array (TMA) was constructed by taking duplicate 0.6 mm cores
from representative regions of each tumor block after review of
hematoxylin- and eosin-stained sections by a pathologist. TMAs
were assembled using a Pathology Devices tissue arrayer
(Westminster, MD).
Immunohistochemistry
Immunohistochemistry for CD20, CD3, CD4, CD8 and
Granzyme B was performed as described in Clarke et al.[12].
The remaining unstained slides were received at the Trev and
Joyce Deeley Research Centre where immunohistochemistry was
performed for CD45RO, TIA-1, FoxP3, CD25, OX-40, CD56,
CD57, CD1a, CD208, myeloperoxidase, CD68, COX-2, MHC
Class I and MHC Class II. Following deparaffinization, the slides
were placed in a Ventana Discovery XT autostainer (Ventana,
Tucson, AZ) for immunohistochemical staining. Ventana’s
standard CC1 protocol was used for antigen retrieval. Primary
antibodies are listed in Table 3.
TMAs were incubated with primary antibodies for 60 minutes
at room temperature, and the appropriate cross-adsorbed,
biotinylated secondary antibody (Jackson Immunoresearch, West
Grove, PA) was applied for 32 minutes. Bound antibodies were
detected using the DABMap kit (Ventana), counterstained with
hematoxylin (Ventana), and coverslipped manually with Cytoseal-
60 (Richard Allan, Kalamazoo, MI).
Histopathological analysis
Immunostained TMAs were examined by a pathologist and
scored using a variety of methods depending on the marker
studied. For CD20, CD8, CD4, CD45RO, TIA-1, Granzyme B,
CD25, OX40, CD1a, CD56, CD57, and myeloperoxidase, only
cells residing within the epithelial compartment of the tumor were
counted. FoxP3 was similarly scored within the epithelium but a
stromal score was also obtained. Tumors were scored as 0 (no
cells), 1 (1-5 cells), 2 (6-19 cells) or 3 (20+ cells); results were
binarized as positive (IHC score 1, 2, or 3) or negative (IHC score
0). CD3 was scored as 0 (no cells present), 1 (cells present in stroma
only), 2 (cells present in the epithelial compartment) or 3 (cells
present in both the epithelial and stromal regions of the tumor);
scores of 0 and 1 were reported as negative while a score of 2 or 3
was reported as positive. CD68 was scored as 0 (no cells present), 1
(luminal or stromal cells), 2 (scattered, ,20 intraepithelial cells), or
3( .20 intraepithelial cells), results were binarized in the same
manner as CD3. COX-2 was scored as 0 (negative), 1 (equivocal,
0-1%), 2 (patchy, .1% to 50%) or 3 (diffuse, .50%) scores of 0
and 1 were reported as negative and scores of 2 or 3 were reported
as positive. For MHC class I and II, samples were scored as 0
(negative), 1 (focal, ,10%), 2 (patchy, 10-50%) or 3 (diffuse,
.50%). Scores of 0, 1 or 2 were reported as negative and scores of
3 were reported as positive.
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Statistical analysis was performed using JMP statistical software
(v7.0) (SAS Institute, Cary, NC). Univariate analysis was carried
out using the Chi-Squared statistic. The log-rank test was used to
compare Kaplan-Meier curves. p-values less than 0.05 were
considered significant.
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